XQuick Search
The Role Of Biomarkers In Predicting Neoadjuvant Treatment Response In Gastric Cancer
Yasin Sezgin, Muslih ÜrünYüzüncü Yıl University Faculty of Medicine, Clinic of Mecical Oncology VanINTRODUCTION: Gastric cancer is still an important health problem in terms of both incidence and mortality. The standard treatment for non-metastatic locally advanced disease is neoadjuvant chemotherapy followed by surgery. In this study, we investigated the role of HALP score and other immunonutritional biomarkers in predicting response to treatment in patients with locally advanced gastric cancer receiving neoadjuvant chemotherapy.
METHODS: A retrospective evaluation was conducted on patients who received neoadjuvant chemotherapy for gastric cancer and were treated and followed up at Van Yüzüncü Yıl University Faculty of Medicine, Dursun Odabaşı Medical Centre and Van Training and Research Hospital between 2015 and 2024. In the study, the following parameters were examined: pre-treatment haemogram parameters, tumour biomarkers, the stage of the disease at the time of diagnosis and the tumour invasion characteristics of the patients. The objective was to ascertain the relationships between these parameters and the response to neoadjuvant treatment.
RESULTS: A total of 183 patients were included in the study, of whom 62 (33.9%) were female and 121 (66.1%) were male. A statistically significant correlation was identified between the treatment response status of the patients and the type of surgery, neural invasion, vascular invasion, TNM classification, HER2 status, and neoadjuvant regimen status (p < 0.05).
DISCUSSION AND CONCLUSION: Our findings indicate that age, neural invasion, vascular invasion, HER2 status and chemotherapy regimen, among clinico-pathological features, and tumour markers (CEA and CA 19-9), white blood cell, lymphocyte and monocyte counts among laboratory values, can predict the response in neoadjuvant patients
Manuscript Language: English